Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

UFS presents sport concussion programme for schools
2008-11-14

The Sports Medicine Clinic at the University of the Free State (UFS) will present a sports concussion programme for schools in the Free State.

“The Pharos Schools Concussion Programme makes the latest methods and technology in concussion management available to learners who play contact sport,” says Dr Louis Holtzhausen, Programme Director of Sports Medicine at the UFS.

The great risk of concussion is that there is an uncertainty about when a player can return to a sport with safety and with the minimum complications in the brain. This programme fills that gap to a large extent.

“By using this programme, no player who suffers concussion will return to play before it is medically safe to do so. The programme also educates players, parents, coaches and the medical fraternity on how to manage sports concussion,” says Dr Holtzhausen.

The programme has been designed for hockey, soccer, cricket, rugby and other contact and collision sports.

SA Rugby has used the programme for professional players for the last five years and advocates that all school rugby players should participate in the programme.

Several sports teams from schools in and around Bloemfontein as well as the University’s Shimla and Irawa rugby teams have already been tested. This will provide invaluable information in the management of possible head injuries.

“We can now give definite guidelines to players and coaches regarding the safe return of players to teams after such an injury. It takes a lot of the guesswork out of the management of concussion and provides peace of mind to coaches, parents and players regarding serious injuries,” says Dr Holtzhausen.

By enrolling in the concussion programme, learners and their parents are ensured of among others:

A baseline computer brain-function test before the start of the season.
Information on how to recognise and treat concussion, including a fieldside information card for the player’s team.
A free consultation and neurological examination by a sports physician after any suspected concussion.
As many brain-function tests and sports-physician consultations as necessary after any concussion, until complete recovery.
Referral to a network of specialists if necessary.

The Pharos Programme uses a cognitive function evaluation called Cogsport. This is a neurophysiological test that measures brain function before the season starts. In this way, a baseline standard is established and, should concussion occur during the season, the extent of it can be measured according to the baseline and rehabilitation.

“Once we have the baseline values, the concussed player’s return to those levels must be monitored. He/she can return to light exercise in the meantime and semi- and full-contact can be introduced at appropriate times,” says Dr Holtzhausen.

The cost of enrolment is R200 per learner, regardless of the number of concussions suffered or sports physician consultations received. “By enrolling in this programme, parents will ensure that their child has the best chance of avoiding the potentially serious consequences of concussion, including learning disabilities, recurrent concussions, epileptic fits and even death,” says Dr Holtzhausen.

More information on the programme can be obtained from Ms Arina Otto at 051 401 2530.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
14 November 2008
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept